Cara Therapeutics, Inc. (CARA) News
Filter CARA News Items
CARA News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
CARA News Highlights
- CARA's 30 day story count now stands at 2.
- Over the past 1 day, the trend for CARA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- TCS and MI are the most mentioned tickers in articles about CARA.
Latest CARA News From Around the Web
Below are the latest news stories about CARA THERAPEUTICS INC that investors may wish to consider to help them evaluate CARA as an investment opportunity.
CARA's Late-Stage Skin Disease Study Fails, Stock Plummets 49%CARA discontinues the clinical program of oral difelikefalin for pruritus associated with atopic dermatitis following the failure of dose-finding Part A of the late-stage study. Stock plunges 49%. |
Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis– Oral difelikefalin as adjunct to topical corticosteroids (TCS) did not demonstrate meaningful clinical benefit compared to TCS alone; As a result, Cara will discontinue its clinical program in pruritus associated with atopic dermatitis – – Late-stage oral difelikefalin clinical programs for pruritus associated with notalgia paresthetica and advanced chronic kidney disease continue to enroll on track with key data readouts expected in 2H24 – – Cara expects to end 2023 with approximately $100 mi |
Cara Therapeutics, Inc. (NASDAQ:CARA) Q3 2023 Earnings Call TranscriptCara Therapeutics, Inc. (NASDAQ:CARA) Q3 2023 Earnings Call Transcript November 13, 2023 Cara Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.52 EPS, expectations were $-0.5. Operator: Good afternoon. My name is Latif and I will be your conference facilitator. I would like to welcome everyone to the Cara Therapeutics Third Quarter Financial Results […] |
Q3 2023 Cara Therapeutics Inc Earnings CallQ3 2023 Cara Therapeutics Inc Earnings Call |
Cara (CARA) Reports Q3 Earnings: What Key Metrics Have to SayThe headline numbers for Cara (CARA) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
Cara Therapeutics Reports Third Quarter 2023 Financial Results– Non-dilutive financing agreement with HealthCare Royalty for up to $40 million expected to extend cash runway into 2025 – – Key data readouts for all three late-stage oral difelikefalin clinical programs anticipated within current financial runway – – Topline results from Part A of KIND 1 Phase 3 atopic dermatitis trial expected in December 2023 – – 3Q23 total revenue of $4.9M including collaborative revenue of $1.9M from the Company’s share of profit of KORSUVA® (difelikefalin) injection – – |
These Biotech Stocks Could Double Your Money, According To AnalystsThe biotech industry has been in the limelight since the COVID-19 pandemic, with public and private sectors pouring in funds to bolster innovation and the development of relevant drugs. Approximately 63% of public biotech firms reported revenue growth in 2021. Emerging biotech companies, which have annual revenue below $500 million, recorded a median 40% annual revenue growth rate, outpacing industry giants, which reported a lower 35% average annual revenue growth rate. While the pandemic-relate |
Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleasePliant Therapeutics, Inc. (PLRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Earnings Preview: Cara Therapeutics (CARA) Q3 Earnings Expected to DeclineCara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
News Flash: Analysts Just Made A Substantial Upgrade To Their Cara Therapeutics, Inc. (NASDAQ:CARA) ForecastsCara Therapeutics, Inc. ( NASDAQ:CARA ) shareholders will have a reason to smile today, with the analysts making... |